NCCN Clinical Practice Guidelines in Oncology: Pediatric Central Nervous System Cancers Version 2.2026
适用人群:<18 岁儿童及青少年中枢神经系统肿瘤;18 岁及以上参照成人脑肿瘤指南。 覆盖病种:髓母细胞瘤、松果体区胚胎性肿瘤、非典型畸胎样 / 横纹肌样瘤(AT/RT)、胶质瘤(低级别胶质瘤 LGG、高级别胶质瘤 HGG、弥漫内生型桥脑胶质瘤 DIPG/DMG)、室管膜瘤、颅咽管瘤、脑膜瘤、脉络丛肿瘤、下丘脑 / 视路胶质瘤、脊髓肿瘤等。 核心原则:分子分型是风险分层、治疗选择的决定性依据;最大安全切除为多数肿瘤首选;优先保护神经认知、内分泌、生长发育;放疗严格限制年龄与剂量,婴幼儿尽量延迟 / 避免放疗;MDT(小儿神经外科、小儿放疗、小儿神经肿瘤、神经病理、影像、内分泌、康复、遗传、社工)强制推荐。 本指南为综合管理框架,各亚型独立路径。
Preface
Pediatric CNS tumors are the most common solid malignancies in childhood, with heterogeneous histology, molecular features and clinical outcomes. The 2026 V2 update integrates methylation profiling, targeted therapy, immunotherapy, proton radiotherapy, and late‑effect surveillance. Management prioritizes preservation of neurologic, endocrine and neurocognitive function while maximizing cure. All specimens are recommended for integrated histologic + molecular + DNA methylation classification.
1. Initial Workup & Staging (All pediatric CNS tumors)
1.1 Pre‑operative evaluation
-
Brain MRI with contrast, multi‑plane sequences; spinal MRI with contrast within 21 days post‑surgery (to avoid postoperative false‑positive leptomeningeal signal)
-
Baseline ophthalmology exam, audiometry, neurocognitive assessment, endocrine baseline panel
-
Baseline neurophysiology, gait, swallowing assessment for brainstem/cerebellar lesions
-
CSF cytology: lumbar puncture, typically ≥10–14 days after surgery to reduce surgical contamination; contraindicated in obstructive hydrocephalus before diversion
-
Germline genetic counseling and germline testing for high‑risk features: AT/RT, SHH‑TP53 mutant medulloblastoma, DICER1, NF1, Li‑Fraumeni, Gorlin, Turcot syndrome, multiple primary tumors, strong family history
-
Molecular panel / DNA methylation array (strong recommendation, category 1 for embryonal tumors, pediatric high‑grade glioma)
-
Functional imaging: PET, perfusion MRI, spectroscopy as adjunct, not routine
1.2 Staging systems
-
Medulloblastoma: Chang staging system
-
Embryonal tumors, AT/RT: CNS M staging (M0–M4)
-
Glioma, ependymoma: TNM and resection status (GTR gross total resection, STR subtotal resection, biopsy only)
-
Diffuse midline glioma (DMG): H3K27M alteration defines diagnosis regardless of histology
2. Tumor‑Specific Management Pathways
2.1 Medulloblastoma
-
Molecular subgroups: WNT‑activated, SHH‑activated (TP53 wild‑type / TP53 mutant), Group 3, Group 4
-
≥3 years old
-
Standard‑risk (WNT M0; non‑WNT M0, GTR, no LC/A, no MYC amplification): reduced‑dose craniospinal irradiation (CSI 23.4 Gy) + posterior fossa/tumor bed boost + vincristine during radiation, followed by adjuvant CCNU/cisplatin/vincristine
-
High‑risk (M+, residual >1.5 cm², LC/A, SHH TP53‑mutant, Group3 MYC‑amplified): CSI 36 Gy + boost, chemotherapy; HDCT‑ASCR for ultra‑high‑risk
-
<3 years old: defer CSI; induction chemotherapy followed by maintenance chemotherapy; focal radiation only for progressive residual disease
-
WNT subgroup: eligibility for radiation de‑escalation in M0 complete resection cases, MDT decision
2.2 Atypical Teratoid/Rhabdoid Tumor (AT/RT)
-
Defining alteration: SMARCB1 (INI1) loss, rarely SMARCA4 loss
-
Highly aggressive, leptomeningeal spread common
-
≥3 years: maximal safe resection, CSI + focal boost + multi‑agent chemotherapy; HDCT‑ASCR considered
-
<3 years: chemotherapy‑first strategy; delayed radiation; intrathecal chemotherapy options
-
Germline SMARCB1 testing strongly recommended for all patients
2.3 Low‑Grade Glioma (LGG, WHO 1/2; pilocytic astrocytoma, diffuse astrocytoma, ganglioglioma, etc.)
-
NF1‑associated optic pathway/hypothalamic glioma: separate pathway; observation if asymptomatic; chemotherapy (carboplatin/vincristine) for progressive symptomatic disease; radiation deferred as long as possible
-
Cerebellar, hemispheric LGG: GTR often curative; observation post GTR
-
Residual/progressive unresectable LGG: chemotherapy first; BRAF V600E positive → BRAF ± MEK inhibitor targeted therapy
-
Radiation reserved for refractory progressive disease; conformal/proton preferred to limit late effects
2.4 Pediatric High‑Grade Glioma & Diffuse Midline Glioma (DMG, formerly DIPG)
-
H3K27M‑mutant DMG: no surgical cure; biopsy for molecular confirmation; focal radiotherapy is standard backbone; chemotherapy/targeted/immunotherapy mostly trial‑based
-
H3G34‑mutant glioma, IDH‑mutant pediatric glioma: distinct molecular subtype, different prognosis
-
Diffuse hemispheric glioma H3 wildtype: resection + chemoradiation; methylation profiling critical
-
Re‑biopsy / liquid biopsy at progression encouraged for trial eligibility
2.5 Ependymoma
-
Posterior fossa ependymoma: PFA, PFB molecular subgroups; supratentorial ependymoma: ZFTA fusion positive etc.
-
GTR is strongest prognostic factor; postoperative focal radiation for ≥1 year old; CSI only for confirmed leptomeningeal metastasis
-
Young infants: chemotherapy to delay radiation; recurrent disease: re‑resection, SBRT, targeted agents, clinical trials
2.6 Craniopharyngioma
-
Adamantinomatous (most pediatric) vs papillary
-
Two strategies: primary GTR (risk of hypothalamic/pituitary injury) or limited resection + adjuvant radiation (proton preferred)
-
Core management: long‑term endocrine replacement (GH, thyroid, cortisol, desmopressin), obesity, sleep, neurocognitive surveillance; cystic progression may use intracystic interferon or bleomycin
-
Avoid aggressive hypothalamic resection when morbidity is high
2.7 Choroid plexus tumors
-
Choroid plexus papilloma (CPP): GTR curative
-
Choroid plexus carcinoma (CPC): high metastatic risk; GTR + chemotherapy; radiation after infancy; HDCT‑ASCR for high risk
2.8 Spinal cord tumors
-
Intramedullary astrocytoma/ependymoma; extradural tumors
-
Surgery first; radiation delayed in young children; spine radiation carries risk of scoliosis, growth impairment, endocrine late effects
3. Radiotherapy Principles (pediatric‑specific)
-
Proton beam therapy is preferred where available for most pediatric CNS tumors, to reduce integral dose to normal brain, cochlea, hypothalamus, pituitary, carotid vessels, growing spine
-
CSI indications strictly limited to embryonal tumors with leptomeningeal risk (medulloblastoma, AT/RT, metastatic ependymoma)
-
Avoid elective whole brain irradiation when focal conformal radiation is sufficient
-
Cochlear dose constraints to preserve hearing (cisplatin + radiation combined ototoxicity is high risk)
-
Re‑irradiation: highly individualized, only oligorecurrent disease, MDT review; risk of radionecrosis, vasculopathy, second neoplasm
4. Supportive Care
-
Hydrocephalus management: ETV vs VP shunt; shunt infection/obstruction surveillance
-
Ototoxicity: serial audiometry; sodium thiosulfate for cisplatin otoprotection per institutional protocol
-
Seizure prophylaxis: not routine; antiepileptic drugs for clinical seizures; avoid enzyme‑inducing AEDs with many targeted agents
-
Posterior fossa syndrome (cerebellar mutism): early speech, occupational, physical therapy
-
Endocrine surveillance: hypothalamic‑pituitary axis injury → hypothyroidism, adrenal insufficiency, GH deficiency, central precocious puberty, diabetes insipidus
-
Thromboembolism: central venous catheter, brain tumor, steroids, surgery increase VTE risk
-
Immunization: update vaccines before immunosuppression; live vaccines contraindicated during profound immunosuppression
5. Survivorship & Late‑Effect Surveillance (mandatory survivorship care plan)
Surveillance schedule stratified by tumor location, surgery, radiation field, chemotherapy agents, germline status
-
Endocrine: lifelong pituitary, thyroid, adrenal, growth, puberty, metabolic screening
-
Neurocognition: IQ, attention, executive function, academic support; highest risk with whole brain/CSI, hypothalamic radiation
-
Neurologic: stroke/moyamoya (especially after suprasellar radiation, NF1), epilepsy, movement disorder
-
Second primary neoplasms: lifelong cancer surveillance; higher risk with germline predisposition and radiation
-
Musculoskeletal: scoliosis, growth retardation, osteopenia/osteoporosis
-
Psychosocial: anxiety, depression, fatigue, transition planning to adult care by 18 years old
-
Fertility and gonadal function: fertility preservation before gonadotoxic chemo/radiation
6. Recurrent / Progressive Pediatric CNS Tumors
-
Re‑staging: brain + spine MRI, CSF cytology, repeat molecular profiling (re‑biopsy or liquid biopsy)
-
Eligibility for clinical trial prioritized (category 1 recommendation)
-
Options: re‑resection, focal SBRT/proton re‑irradiation, HDCT‑ASCR, targeted therapy based on molecular alteration, immunotherapy
-
Early palliative care integration for symptomatic, progressive disease
7. 2026 V2 Key Updates
-
DNA methylation profiling upgraded to category 1 recommendation for all embryonal tumors and pediatric high‑grade glioma for accurate classification
-
Refined DMG/H3K27M pathway: harmonized trial eligibility and targeted therapy recommendations
-
Ependymoma molecular subgroup guidance expanded (PFA/PFB, ZFTA fusion) to guide radiation and chemotherapy intensity
-
AT/RT: updated intrathecal chemotherapy and HDCT sequencing; standardized germline SMARCB1 testing
-
LGG: BRAF/MEK inhibitor monitoring guidance (ocular toxicity, cardiac surveillance) strengthened
-
Craniopharyngioma: formal consensus on hypothalamic sparing strategy; cyst‑directed therapy algorithm
-
New late‑effect section: cerebrovascular screening (MRA for moyamoya) for patients receiving suprasellar radiation
-
Clarified transition checklist: pediatric CNS survivor handoff to adult neuro‑oncology at 17–18 years old, with full treatment summary and endocrine surveillance plan
-
Radiation note: proton therapy preference extended to ependymoma and craniopharyngioma, not only medulloblastoma
8. Disclaimer
This guideline covers pediatric CNS tumor framework. Specific chemotherapy regimens, targeted agents, and radiation dose prescriptions are within each tumor subtype module. All children should be managed at centers with pediatric neuro‑oncology expertise when feasible.
Citation
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Pediatric Central Nervous System Cancers Version 2.2026. NCCN.org.